Tudor Investment Corp ET AL Acquires 437,690 Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC)

Tudor Investment Corp ET AL grew its position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) by 295.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 585,865 shares of the medical technology company's stock after purchasing an additional 437,690 shares during the period. Tudor Investment Corp ET AL owned about 0.41% of Alphatec worth $5,378,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. American Century Companies Inc. raised its position in shares of Alphatec by 36.5% during the fourth quarter. American Century Companies Inc. now owns 4,989,057 shares of the medical technology company's stock worth $45,800,000 after purchasing an additional 1,334,780 shares during the period. Marshall Wace LLP raised its holdings in shares of Alphatec by 139.2% during the fourth quarter. Marshall Wace LLP now owns 1,773,246 shares of the medical technology company's stock worth $16,278,000 after acquiring an additional 1,032,070 shares during the period. Emerald Advisers LLC lifted its position in Alphatec by 112.4% in the 4th quarter. Emerald Advisers LLC now owns 1,456,033 shares of the medical technology company's stock valued at $13,366,000 after acquiring an additional 770,586 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Alphatec by 119.3% during the 4th quarter. Bank of New York Mellon Corp now owns 662,239 shares of the medical technology company's stock worth $6,079,000 after purchasing an additional 360,258 shares in the last quarter. Finally, Congress Asset Management Co. raised its stake in shares of Alphatec by 235.4% in the 4th quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company's stock valued at $3,993,000 after purchasing an additional 305,296 shares during the period. 66.35% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently issued reports on ATEC. Barclays increased their price objective on Alphatec from $20.00 to $21.00 and gave the stock an "overweight" rating in a report on Wednesday, January 22nd. Piper Sandler reissued an "overweight" rating and issued a $15.00 price objective (up previously from $13.00) on shares of Alphatec in a research report on Friday. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Alphatec in a research report on Monday, April 14th. Needham & Company LLC restated a "buy" rating and set a $16.00 price objective on shares of Alphatec in a research note on Friday. Finally, StockNews.com raised Alphatec from a "sell" rating to a "hold" rating in a research report on Friday, February 28th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, Alphatec presently has an average rating of "Moderate Buy" and a consensus target price of $17.89.

Insider Transactions at Alphatec

In other news, COO Scott Lish sold 27,453 shares of the stock in a transaction that occurred on Thursday, February 6th. The stock was sold at an average price of $11.49, for a total transaction of $315,434.97. Following the transaction, the chief operating officer now owns 867,677 shares in the company, valued at approximately $9,969,608.73. This trade represents a 3.07 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP David Sponsel sold 33,732 shares of the business's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $10.83, for a total value of $365,317.56. Following the completion of the sale, the executive vice president now owns 668,977 shares of the company's stock, valued at $7,245,020.91. This trade represents a 4.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 222,113 shares of company stock worth $2,519,725. 22.80% of the stock is owned by insiders.

Alphatec Stock Performance

NASDAQ ATEC traded up $0.94 during trading on Friday, reaching $12.00. 4,701,141 shares of the company's stock were exchanged, compared to its average volume of 2,074,909. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The business has a 50 day moving average price of $10.46 and a 200-day moving average price of $9.89. The stock has a market capitalization of $1.75 billion, a P/E ratio of -9.38 and a beta of 1.20. Alphatec Holdings, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $13.79.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The business had revenue of $169.18 million for the quarter, compared to analyst estimates of $167.57 million. During the same period in the previous year, the firm posted ($0.34) earnings per share. The firm's revenue was up 22.2% compared to the same quarter last year. Sell-side analysts forecast that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.